ANTIMALARIAL THERAPIES IN CHILDREN IN PAPUA NEW GUINEA
Change and challenge is in the wind as 2008 comes to an end. The same is true when examining this month's ReachMD XM160 special series Focus on Global Medicine. We take a look at both the changes and the challenges impacting global medicine.
Malaria control is difficult where there is intense year around transmission of multiple species. What do the results from the life of clinical trial in Papua New Guinea tell us about treating this disease?
You are listening to ReachMD XM160, The Channel for Medical Professionals. Welcome to a special segment Focus on Global Health. I am Dr. Mary Leuchars, your host and joining me today from Perth, Australia is Dr. Tim Davis. Dr. Davis is Professor of Medicine at the University of Western Australia. Today, we are discussing the results from his clinical trial published in the life of New England Journal of Medicine, a combination antimalarial therapies in children from Papua New Guinea (OPNG).
DR. MARY LEUCHARS:
Welcome, Dr. Davis.
DR. TIM DAVIS:
Hi there.
DR. MARY LEUCHARS:
Now can you tell me why you and your colleagues chose PNG for this particular trial?
DR. TIM DAVIS:
DR. MARY LEUCHARS:
DR. TIM DAVIS:
DR. MARY LEUCHARS:
DR. TIM DAVIS:
DR. MARY LEUCHARS:
DR. TIM DAVIS:
DR. MARY LEUCHARS:
DR. TIM DAVIS:
DR. MARY LEUCHARS:
DR. TIM DAVIS:
DR. MARY LEUCHARS:
Facebook Comments